← Sionna Therapeutics, Inc. Common Stock overview

Sionna Therapeutics, Inc. Common Stock vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sionna Therapeutics, Inc. Common Stock (SION)

Q3 2026
▼3▲1

Sionna's lead CF drug failed; now it's cutting costs and betting on a backup

  • Lead cystic fibrosis drug failed its key trial SION-719, Sionna's main drug, did not meaningfully improve CFTR function in a Phase 2a trial — the sweat chloride change was tiny and not statistically significant. The company dropped it as a Trikafta add-on. Since the stock's value rested on this drug, shares collapsed over 90%.

    This is the single biggest force behind SION's move and the root cause of everything that followed.

  • Rival Vertex strengthened as Sionna's threat faded With Sionna's add-on approach shelved, Vertex's dominant cystic fibrosis franchise faces less competition, and Vertex shares hit new highs. That matters for Sionna because the market now sees a harder path to winning any share of the CF market.

    It explains the competitive backdrop that makes Sionna's setback worse for its long-term value.

  • 46% workforce cut to save cash after the failure Sionna is cutting nearly half its staff, costing about $6.4 million, to lower spending and stretch its cash into the second half of 2029. It's a sign of retrenchment, but it also buys time to develop the backup program.

    It shows the concrete financial and operational fallout of the trial failure, which drives the stock lower.

  • Backup combo shows promise ahead of 2027 trial Sionna is now focused on SION-451 plus SION-2222, which it will test in the AscenSION Phase 2a trial starting early 2027. New preclinical data showed these NBD1 stabilizers improved CFTR function up to normal levels, offering a possible path forward.

    It is the main counterweight — the remaining reason investors see any value in Sionna after the failure.

September 2026
▼3▲1

Sionna's lead CF drug failed; now it's cutting costs and betting on a backup

  • Lead cystic fibrosis drug failed its key trial SION-719, Sionna's main drug, did not meaningfully improve CFTR function in a Phase 2a trial — the sweat chloride change was tiny and not statistically significant. The company dropped it as a Trikafta add-on. Since the stock's value rested on this drug, shares collapsed over 90%.

    This is the single biggest force behind SION's move and the root cause of everything that followed.

  • Rival Vertex strengthened as Sionna's threat faded With Sionna's add-on approach shelved, Vertex's dominant cystic fibrosis franchise faces less competition, and Vertex shares hit new highs. That matters for Sionna because the market now sees a harder path to winning any share of the CF market.

    It explains the competitive backdrop that makes Sionna's setback worse for its long-term value.

  • 46% workforce cut to save cash after the failure Sionna is cutting nearly half its staff, costing about $6.4 million, to lower spending and stretch its cash into the second half of 2029. It's a sign of retrenchment, but it also buys time to develop the backup program.

    It shows the concrete financial and operational fallout of the trial failure, which drives the stock lower.

  • Backup combo shows promise ahead of 2027 trial Sionna is now focused on SION-451 plus SION-2222, which it will test in the AscenSION Phase 2a trial starting early 2027. New preclinical data showed these NBD1 stabilizers improved CFTR function up to normal levels, offering a possible path forward.

    It is the main counterweight — the remaining reason investors see any value in Sionna after the failure.

Latest
▼3▲1

Sionna's lead CF drug failed; now it's cutting costs and betting on a backup

  • Lead cystic fibrosis drug failed its key trial SION-719, Sionna's main drug, did not meaningfully improve CFTR function in a Phase 2a trial — the sweat chloride change was tiny and not statistically significant. The company dropped it as a Trikafta add-on. Since the stock's value rested on this drug, shares collapsed over 90%.

    This is the single biggest force behind SION's move and the root cause of everything that followed.

  • Rival Vertex strengthened as Sionna's threat faded With Sionna's add-on approach shelved, Vertex's dominant cystic fibrosis franchise faces less competition, and Vertex shares hit new highs. That matters for Sionna because the market now sees a harder path to winning any share of the CF market.

    It explains the competitive backdrop that makes Sionna's setback worse for its long-term value.

  • 46% workforce cut to save cash after the failure Sionna is cutting nearly half its staff, costing about $6.4 million, to lower spending and stretch its cash into the second half of 2029. It's a sign of retrenchment, but it also buys time to develop the backup program.

    It shows the concrete financial and operational fallout of the trial failure, which drives the stock lower.

  • Backup combo shows promise ahead of 2027 trial Sionna is now focused on SION-451 plus SION-2222, which it will test in the AscenSION Phase 2a trial starting early 2027. New preclinical data showed these NBD1 stabilizers improved CFTR function up to normal levels, offering a possible path forward.

    It is the main counterweight — the remaining reason investors see any value in Sionna after the failure.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.